Place/Date: - April 13th, 2021 at 2:00 pm UTC · 3 min read Contact: Enso,
Source: Enso
Enso finance, a strategy-creation platform offering anyone to create composable and permissionless strategies, has completed its private fundraising round co-led by Polychain Capital and Dfinity Beacon Fund. Multicoin Capital, P2P Capital, Spartan Group, Zola Global, and The LAO participated in the round as well, alongside angel investors from AngelList, Dfinity, Synthetix, Status, Fantom, Nexus Mutual, Aave and Messari. These funds will be used to fund platform development, community expansion, and a successful mainnet launch in Q2 2021.
Enso was created as a tool to simplify and create solutions to increase access to DeFi strategies and to enable frictionless trading. With over $50 billion locked in DeFi, the trading landscape has become highly fragmented, making it more complex to trade efficiently, hedge accordingly, or generate yield effectively.
What it does:10x Genomics makes software for researchers to perform single cell and whole genome sequencing. Its software can be used for immunotherapy and cell therapy research in cancer patients or patients with rare genetic disorders. The Silicon Valley-based company was founded by Serge Saxonov, formerly the founding director of research at consumer genetics company 23andMe.
Deal details: SoftBank participated in the company s $125 million Series D funding round in 2018 that valued the company at $1.25 billion. It went public in September 2019 and was valued above $3.6 billion in its debut. SoftBank is no longer invested in 10x Genomics.
Other investors: Venrock, Fidelity International, Foresight Capital Management, and Paladin Capital Group